| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 10, 2023 |
| Accession Number: | 0001193125-23-202972 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 10, 2023 |
| Accession Number: | 0001193125-23-202972 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Peak Bio, Inc. (0001834645) (Issuer)
4/A - Peak Bio, Inc. (0001834645) (Issuer)
4 - Peak Bio, Inc. (0001834645) (Issuer)
4 - Peak Bio, Inc. (0001834645) (Issuer)
4/A - Peak Bio, Inc. (0001834645) (Issuer)
4 - Peak Bio, Inc. (0001834645) (Issuer)
8-K - Peak Bio, Inc. (0001834645) (Filer)
8-K - Peak Bio, Inc. (0001834645) (Filer)
8-K - Peak Bio, Inc. (0001834645) (Filer)
Combined Company Scheduled to Commence Trading on NASDAQ Under the Ticker Symbol "PKBO" Peak Bio Co., Ltd. ("Peak Bio"), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the "Business Combination") with Ignyte Acquisition Corp. (NASDAQ:IGNY) ("Ignyte"), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte's stockholders held on October 25, 2022 (the "Special Meeting"). Ignyte's stockholders also voted to approve all other proposals presented at the Special Meeting. Ignyte's Board of Direct
Transaction Expected to Close on October 31, 2022 Ignyte Acquisition Corp. ("Ignyte") (NASDAQ:IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte's stockholders have approved its proposed business combination (the "Business Combination") with Peak Bio Co., Ltd. ("Peak Bio") at a Special Meeting of its stockholders held on October 25, 2022 (the "Special Meeting"). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Special Meeting, representing approximately 75% of Ignyte's outstanding shares of common stock entitled to vote at the Special Meeting, were cast in favor of the proposal to approv
- Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A
SC 13D - Peak Bio, Inc. (0001834645) (Subject)
SC 13G - Peak Bio, Inc. (0001834645) (Subject)
SC 13G/A - Peak Bio, Inc. (0001834645) (Subject)
- Company to be led by Hoyoung Huh, M.D. Ph.D., serial entrepreneur / investor with notable public and private biotech board positions - $25 million private investment in public equity ("PIPE") with participation from leading healthcare institutional investor, Palo Alto Investors (PAI) with additional participation from Peak Bio's CEO, Hoyoung Huh, MD, Ph.D. - Differentiated pipeline includes next generation Neutrophil Elastase Inhibitor targeting AATD / ARDS and robust preclinical ADC oncology platform utilizing Antibody Drug Conjugates - Anticipated cash at closing expected to fully fund the company through 2024 allowing for multiple milestones in ADC program and interim Phase II for A